MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

34.71 -1.64

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

34.46

Max

34.84

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+32.94% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.7B 5.8B
Iepriekšējā atvēršanas cena	36.35
Iepriekšējā slēgšanas cena	34.71

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. janv. 22:45 UTC

Galvenie tirgus virzītāji

GH Research Shares Up, Plans to Provide Update on New Drug Application

2026. g. 2. janv. 22:13 UTC

Tirgus saruna

Peļņas

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 21:07 UTC

Peļņas

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2026. g. 2. janv. 20:09 UTC

Tirgus saruna

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2026. g. 2. janv. 19:48 UTC

Tirgus saruna

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2026. g. 2. janv. 17:56 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2026. g. 2. janv. 17:50 UTC

Tirgus saruna

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2026. g. 2. janv. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 16:33 UTC

Tirgus saruna

Remittances to Mexico Fell 5.7% in November -- Market Talk

2026. g. 2. janv. 16:18 UTC

Tirgus saruna

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2026. g. 2. janv. 15:48 UTC

Peļņas

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2026. g. 2. janv. 15:17 UTC

Tirgus saruna

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2026. g. 2. janv. 15:01 UTC

Tirgus saruna

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2026. g. 2. janv. 15:00 UTC

Peļņas

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2026. g. 2. janv. 14:56 UTC

Tirgus saruna

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. janv. 14:13 UTC

Tirgus saruna

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2026. g. 2. janv. 13:39 UTC

Tirgus saruna

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2026. g. 2. janv. 13:01 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2026. g. 2. janv. 12:45 UTC

Tirgus saruna

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2026. g. 2. janv. 11:48 UTC

Tirgus saruna

European Gas Climbs as Cold Weather Bites -- Market Talk

2026. g. 2. janv. 11:36 UTC

Tirgus saruna

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2026. g. 2. janv. 11:30 UTC

Tirgus saruna

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2026. g. 2. janv. 11:29 UTC

Tirgus saruna

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2026. g. 2. janv. 11:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

32.94% augšup

Prognoze 12 mēnešiem

Vidējais 47.22 USD 32.94%

Augstākais 67 USD

Zemākais 34 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.